FDA reminds patients and healthcare providers about risks associated with recalled Exactech replacement joint devices that were packaged in defective ...
Regeneron and Sanofi say an investigational Phase 3 trial of Dupixent in some COPD patients met all key primary and secondary endpoints.
The Government Accountability Office reports on regenerative medicine and advanced therapies workforce and education/training needs.
A new White House Office of Science and Technology Policy (OSTP) report lists 10 bold goals for the U.S. biotechnology and biomanufacturing.
CDRH director Jeff Shuren tells an Alliance for Stronger FDA Webinar that cybersecurity is one of the biggest concerns that keeps him up at night.
FDA approves a Cidara Therapeutics and Melinta Therapeutics NDA for Rezzayo (rezafungin for injection) for treating candidemia and invasive candidiasi...
The Federal Trade Commission asks the Delaware federal court to consider four antitrust implications in deciding whether to grant a Supurnus motion to...
FDA issues AbbVie a complete response letter for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in adults with advanced Parkinson...
